Literature DB >> 3008616

Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy.

R T Schooley, R W Carey, G Miller, W Henle, R Eastman, E J Mark, K Kenyon, E O Wheeler, R H Rubin.   

Abstract

Two patients developed fever, interstitial pneumonitis, and pancytopenia associated with extremely high titers of antibody to replicative antigens of the Epstein-Barr virus. In contrast to most patients seropositive for Epstein-Barr virus, neither patient had an antibody response to the Epstein-Barr nuclear antigen K polypeptide. In addition, virus isolated from one patient had a deletion of the B95-8 type in the EcoRI C region of the genome. An etiologic relation between Epstein-Barr virus replication and the clinical manifestations of this syndrome is further shown by the response of each patient to acyclovir therapy. These patients have a new Epstein-Barr-virus-associated syndrome and provide additional evidence that acyclovir may play a role in therapy for selected patients with Epstein-Barr virus infection.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3008616     DOI： 10.7326/0003-4819-104-5-636

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


  29 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.

Authors:  Christos Stefanou; Christiana Tzortzi; Fotini Georgiou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-12-09

3.  Differences among human immunodeficiency virus strains in their capacities to induce cytolysis or persistent infection of a lymphoblastoid cell line immortalized by Epstein-Barr virus.

Authors:  K Dahl; K Martin; G Miller
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Acyclovir treatment in infectious mononucleosis: a clinical and virological study.

Authors:  J Andersson; B Sköldenberg; W Henle; J Giesecke; A Ortqvist; I Julander; E Gustavsson; B Akerlund; S Britton; I Ernberg
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection.

Authors:  W Henle; G Henle; J Andersson; I Ernberg; G Klein; C A Horwitz; G Marklund; L Rymo; C Wellinder; S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

Review 6.  Severe chronic active Epstein-Barr virus infection syndrome.

Authors:  M Okano; S Matsumoto; T Osato; Y Sakiyama; G M Thiele; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  Epstein - Barr virus Pneumonitis.

Authors:  Terence E McManus; Peter V Coyle; John Lawson; J Stuart Elborn; Joseph C Kidney
Journal:  Ulster Med J       Date:  2009-05

Review 8.  Epstein-Barr virus infection and associated diseases in children. II. Diagnostic and therapeutic strategies.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

9.  Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers.

Authors:  B G Petty; R J Whitley; S Liao; H C Krasny; L E Rocco; L G Davis; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

10.  Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection.

Authors:  H Kimura; I Tsuge; S Imai; M Yamamoto; K Kuzushima; T Osato; T Morishima
Journal:  Med Microbiol Immunol       Date:  1995-08       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.